What question did this study set out to answer?

This study aims to analyze the clincio-epidemiological profile and effectiveness of systemic therapies in localized non-uterine leiomyosarcoma in India.

March 12, 2026Open Access

158P Clinico-epidemiological profile, systemic therapy effectiveness, and survival outcomes in localised non-uterine leiomyosarcoma: Real-world evidence from India

Key Points

This study aims to analyze the clincio-epidemiological profile and effectiveness of systemic therapies in localized non-uterine leiomyosarcoma in India.
Data gathered from a decade-long real-world study with a focus on treatment regimens.
Evaluated effectiveness of various systemic therapies including doxorubicin and pazopanib.
Employed next-generation sequencing to assess genetic mutations.
Disease-control rate was 74.2%, with median progression-free survival of 6.73 months.
Overall survival was found to be 10.64 months across different treatment regimens.
Less intensive treatments showed effectiveness similar to multi-agent therapies with better tolerability.
Grade 3-4 toxicities, primarily hematological, were observed, with neutropenia being the most common.

Abstract

7%), doxorubicin-ifosfamide (16.4%), gemcitabine-docetaxel (12.9%), and pazopanib (12.9%).The disease-control rate was 74.2%.Median progression-free survival (PFS) and overall survival (OS) were 6.73 and 10.64 months, respectively, with no significant differences across primary or metastatic sites.Notably, less intensive regimens such as single-agent doxorubicin and pazopanib achieved progression-free survival comparable to multi-agent therapies (6.7 vs 6.73 months; p = 0.7 for doxorubicin, and 10.4 vs 6.73 months; p = 0.3 for pazopanib) while demonstrating more favorable tolerability.Grade 3-4 toxicities were predominantly hematological, especially neutropenia.Next-generation sequencing in 27 showed no alteration in 12(44%) patients, TP53 mutations in 8(30%), BRCA2 mutations in two (7%) patients, and isolated CDKN2A, GNAQ, PTEN, MEN1, and FGFR amplifications.Conclusions: This decade-long real-world study provides one of the largest LMIC datasets of metastatic non-uterine LMS.Systemic therapy outcomes remain modest despite diverse treatment strategies.Future efforts must prioritize biomarker-integrated clinical trials, exploration of novel therapeutic targets, and optimization of treatment sequencing to meaningfully advance patient outcomes.

KI fragen

Bookmark

View Full Paper